Dr. Richard Creager has more than 35 years of experience in the in vitro diagnostic industry. Currently, he is President & CEO of Seegene USA, Inc., the US-based division of Seegene Inc. a global developer of infectious disease molecular diagnostic products. Previously, Dr. Creager was a consultant to The National Institutes of Health (NIH) RADx initiative to speed innovation in the development and commercialization of COVID19 diagnostic tests. This program is now delivering more than 500 million diagnostic tests/month to US healthcare professionals and consumers. Dr. Creager also was a consultant to other diagnostic companies developing diagnostic tests for prostate and other cancers. Previously Richard was Senior Vice President and Chief Science Officer for Beckman Coulter, a division of Danaher Corporation. During his career, Dr. Creager led the development of more than 170 IVD products for infectious disease, cardiovascular disease, oncology, autoimmune disease, and endocrine disorders. He also led the development and commercialization of several innovative tests for acute myocardial infarction; AMH, for the assessment of ovarian reserve; and the Prostate Health Index (PHI), a test intended to reduce the number of unnecessary prostate biopsies in men. Richard has a B.S. from Muhlenberg College, a M.S. from Duquesne University, and a Ph.D. from the University of Pittsburgh School of Medicine. He also attended The Wharton School of Business for Advanced Management Program.